Physician profile
Ryan G Gamble
NPI 1881988913
$10,371.82
in general payments reported to CMS, 2019-2025
33 companies · $2,434 in 2025
The $2,434 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $470 · 2021: $941 · 2022: $1,299 · 2023: $1,896 · 2024: $2,304 · 2025: $2,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,439 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,439.39 |
| Education | $194.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,588.80 | 2019-2025 | |
| Janssen Biotech, INC. | $1,134.30 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $915.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $762.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $642.28 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $528.31 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $504.85 | 2019-2025 | Winlevi |
| Pfizer INC. | $415.85 | 2021-2025 | |
| Lilly USA, LLC | $401.19 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Leo Pharma INC. | $354.91 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $330.46 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $307.53 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.83 | 2019-2022 | |
| Galderma Laboratories, L.P. | $232.10 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $159.74 | 2022-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $139.65 | 2023-2025 | Zoryve |
| Almirall LLC | $102.08 | 2019-2022 | |
| Organon LLC | $101.17 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $77.34 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $56.15 | 2022-2023 | Valchlor |
| Genentech USA, INC. | $51.34 | 2019 | |
| Ucb, INC. | $44.88 | 2023-2024 | Bimzelx, Cimzia |
| Epi Health, LLC | $38.38 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $33.83 | 2020 | |
| Mayne Pharma Commercial LLC | $28.46 | 2019 | |
| Celgene Corporation | $27.16 | 2019 | |
| Verrica Pharmaceuticals INC. | $26.80 | 2023 | Ycanth |
| Mallinckrodt Hospital Products INC. | $25.97 | 2024 | Acthar |
| Kyowa Kirin, INC. | $24.39 | 2025 | |
| Merck Sharp & Dohme LLC | $22.36 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.18 | 2019 | |
| Dermira, INC. | $15.94 | 2020 | |
| Aclaris Therapeutics, INC. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.